About Us
Overview
Our History
Leadership Team
Partner
Portfolio Advisory Board
Media Center
Our Science
Science & Innovation
Dorzagliatin
mGluR5
Presentations
Peer Reviewed Publications
Products&Pipeline
Pipeline
HuaTangNing(华堂宁®)
Media
Company News
Media Releases
Video
Investor Relations
Investor Center
Corporate Governance
Financial Report
Announcements and Circulars
Listing Documents
Investor Presentation
IR Contact
Investor Calendar
Stock Information (2552.HK)
Corporate Communications
Careers
Company Culture
Join Us
Contact Us
中
中
中

Our Science

 >  Our Science
 >  Presentations
Science & Innovation
Dorzagliatin
mGluR5
Presentations
Peer Reviewed Publications

Fragile X syndrome as a rare disease in China - Therapeutic challenges and opportunities.

2015 February/ Intractable & Rare Diseases Research
Hua Medicine
Feb 01, 2015
7642
Share

Online link unavailable, presentation available upon request. (BD@huamedicine.com)

Return list
Previous Page：
A Novel Dual Pancreatic and Hepatic Acting Glucokinase Activator, HMS5552: Phase I Studies in Healthy Subjects and T2DM Patients
Next Page：
葡萄糖激酶激活剂HMS5552对2型糖尿病大鼠肝组织中葡萄糖激酶的调节作用 （2015 CDS）
About Us
Overview
Our History
Leadership Team
Portfolio Advisory Board
Partner
Media center
Research & Development
Inovation
Dorzagliatin
mGluR5
Presentations
Peer Reviewed Publications
Media
Company News
Media Releases
Video
Investor Relations
Corporate Governance
Financial Report
Announcements & Circulars
Listing Documents
Investor Presentation
IR Contact
Investor Calendar
Stock information
Careers
Culture
Join Us
Products&Pipeline
Pipeline
HuaTangNing(华堂宁®)
Focus Us
Copyright © 2025  Hua Medicine (Shanghai) Ltd.    沪网药械信备字【2026】000123号
沪ICP备14036654号-1  beiantubiao.png 沪公网安备 31011502013809号  Privacy Statement  Terms of Use
Search
How we use cookies
Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.
Accept
x